0001104659-23-093913.txt : 20230821 0001104659-23-093913.hdr.sgml : 20230821 20230821160629 ACCESSION NUMBER: 0001104659-23-093913 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230817 FILED AS OF DATE: 20230821 DATE AS OF CHANGE: 20230821 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McKenna Mark C. CENTRAL INDEX KEY: 0001749623 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41740 FILM NUMBER: 231189185 MAIL ADDRESS: STREET 1: 400 SOMERSET CORPORATE BOULEVARD CITY: BRIDGEWATER STATE: NJ ZIP: 08807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Apogee Therapeutics, Inc. CENTRAL INDEX KEY: 0001974640 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 880588063 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 221 CRESCENT ST. STREET 2: BUILDING 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 650-394-5230 MAIL ADDRESS: STREET 1: 221 CRESCENT ST. STREET 2: BUILDING 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: Apogee Therapeutics, LLC DATE OF NAME CHANGE: 20230420 4 1 tm2324209-2_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-08-17 0 0001974640 Apogee Therapeutics, Inc. APGE 0001749623 McKenna Mark C. C/O APOGEE THERAPEUTICS, INC. 221 CRESCENT ST., BLDG. 17, STE. 102B WALTHAM MA 02453 1 0 0 0 0 Stock Option (Right to Buy) 23.60 2023-08-17 4 A 0 50000 0.00 A 2033-08-17 Common Stock 50000 50000 D Stock Option (Right to Buy) 23.60 2023-08-17 4 A 0 100000 0.00 A 2033-08-17 Common Stock 100000 150000 D This option represents the right to purchase 50,000 shares of the Issuer's common stock, which will vest in thirty-six equal monthly installments over a three-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer. This option represents the right to purchase 100,000 shares of the Issuer's common stock, which will vest in thirty-six equal monthly installments over a three-year period from the date of grant, contingent upon approval of the option at the Issuer's 2024 Annual Meeting of Stockholders and subject to the Reporting Person's continued service to the Issuer. /s/ Matthew Batters, as attorney-in-fact for Mark McKenna 2023-08-21